Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD3 epsilon, Mouse anti-Human, Clone: C3e/1931, Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP279706100UG
Description
CD3 epsilon Monoclonal specifically detects CD3 epsilon in Human samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin, Protein Array.Specifications
CD3 epsilon | |
Monoclonal | |
0.2 mg/mL | |
Western Blot 1-2 ug/ml, Flow Cytometry 1-2 ug/million cells, ELISA 2-4 ug/ml, Immunohistochemistry 1-2 ug/ml, Immunohistochemistry-Paraffin 1-2 ug/ml, Protein Array | |
P07766, P07766 | |
CD3E | |
A recombinant human CD3 epsilon protein fragment (around aa 23-119) (exact sequence is proprietary) | |
100 μg | |
Adaptive Immunity, Apoptosis, Cytokine Research, Diabetes Research, Immunology, Innate Immunity, Signal Transduction, Stem Cell Lines, Stem Cell Markers | |
916 | |
Human | |
Purified |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunohistochemistry (Paraffin), Peptide Array | |
C3e/1931 | |
Unconjugated | |
10 mM PBS with 0.05% BSA | |
CD3e antigen, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), CD3-epsilon, FLJ18683, T3E, T-cell antigen receptor complex, epsilon subunit of T3, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, TCRE | |
Mouse | |
Protein A or G purified | |
RUO | |
Primary | |
This antibody recognizes the epsilon-chain of CD3, which consists of five different polypeptide chains (designated as gamma, delta, epsilon, zeta, and eta) with MW ranging from 16-28kDa. | |
Store at 4°C. | |
IgG1 κ |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction